AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15172894
Drug: Intranasal budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal budesonide for 2 weeks
Trial: 8088139
Drug: 5% SLS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% SLS solution
Trial: 8088139
Drug: 7.5% SLS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5% SLS solution
Trial: 1234581
Drug: Variable insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Variable insulin doses
Trial: 1234581
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of biguanides (metformin)
Trial: 25745751
Drug: Cabergoline (Cb2)
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabergoline (Cb2) 0.5 mg oral per day for 8 consecutive days starting on the day of hCG administration
Trial: 17031013
Drug: 5 microg
RxNorm normalized name: Digoxin 125 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 microg of vitamin D3 daily
Trial: 17031013
Drug: 20 microg
RxNorm normalized name: Calcifediol 20 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 microg of vitamin D3 daily
Trial: 28639987
Drug: Unfractioned heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfractioned heparin
Trial: 3327683
Drug: Felodipine (0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (0.075 mg/kg)
Trial: 29895045
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (34 children) participated in two gaming sessions (1.5 hours each) and an oral presentation about smoking and alcohol risks.
Trial: 11134123
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg oral DHEA daily for 12 weeks
Trial: 3023457
Drug: Topical alpha
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical alpha interferon gel (10^7 U) with nonoxynol 9 applied three times daily for 5 days
Trial: 17584560
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Telmisartan and Ramipril
Trial: 25302016
Drug: KM-023 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KM-023 75 mg
Trial: 25302016
Drug: KM-023 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KM-023 150 mg
Trial: 25302016
Drug: KM-023 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KM-023 300 mg
Trial: 25302016
Drug: KM-023 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KM-023 600 mg
Trial: 25302016
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of KM-023 75 mg
Trial: 17631698
Drug: SR-CAP (sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR-CAP (sustained-release pellet formulation of diclofenac, 100 mg, once daily)
Trial: 7859964
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of intravenous cefotaxime
Trial: 2911170
Drug: Dexamethasone acetate
RxNorm normalized name: Dexamethasone Acetate
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone acetate 4 mg every six hours for six doses starting at exposure (2700 m)
Trial: 2911170
Drug: Placebo every
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo every six hours for six doses starting at exposure (2700 m)
Trial: 2911170
Drug: Dexamethasone acetate
RxNorm normalized name: Dexamethasone Acetate
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone acetate 4 mg every six hours for six doses starting at exposure (2050 m)
Trial: 2911170
Drug: Placebo every
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo every six hours for six doses starting at exposure (2050 m)
Trial: 21287560
Drug: Minocycline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline (2 × 50 mg/d)
Trial: 16814009
Drug: Cognitive-behavioral (CB)
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral (CB) treatment
Trial: 12202014
Drug: 12-step treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-step treatment
Trial: 15035271
Drug: Conventional-dose mannitol
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional-dose mannitol treatment (approximately 0.7 g/kg)
Trial: 11318075
Drug: 85% NPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 85% NPH insulin and 15% regular human insulin (85/15)
Trial: 11318075
Drug: 70% NPH/30%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70% NPH/30% regular human insulin (70/30)
Trial: 11318075
Drug: 100% NPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% NPH insulin
Trial: 3580233
Drug: morphine 10
RxNorm normalized name: morphine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 10 mg plus cisapride 10 mg
Trial: 3580233
Drug: morphine 10
RxNorm normalized name: morphine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 10 mg plus cisapride 4 mg
Trial: 31351965
Drug: GZ389988A (tropomyosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GZ389988A (tropomyosin receptor kinase A inhibitor)
Trial: 12628875
Drug: Amoxicillin-clavulanate for
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate for 6 weeks followed by nasal saline solution irrigation for 6 weeks
Trial: 12628875
Drug: Nasal saline
RxNorm normalized name: Nasal Saline
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasal saline solution irrigation for 12 weeks (for children without chronic sinusitis)
Trial: 9354220
Drug: Saline instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline instillation (1 mL/kg; maximum 10 mL) before catheter removal
Trial: 30427135
Drug: Dermal equivalent
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermal equivalent (DE) applied on trophic ulcers in addition to standard treatment
Trial: 18662287
Drug: Lamotrigine 200
RxNorm normalized name: lamotrigine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine 200 mg b.d.
Trial: 9613910
Drug: Lovastatin (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (20-40 mg daily)
Trial: 29031763
Drug: Sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium oxybate treatment in SXB-15
Trial: 29031763
Drug: Sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium oxybate treatment in SXB-22
Trial: 25934164
Drug: LNG20 (52-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNG20 (52-mg levonorgestrel intrauterine contraceptive)
Trial: 23857972
Drug: Sunitinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib plus capecitabine (2,000 mg/m2)
Trial: 3961002
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg hydrocortisone
Trial: 23945999
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg hydrocortisone
Trial: 17143357
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) 0.5 g/kg over 4 hours, every 12 hours for 3 doses
Trial: 14673697
Drug: Transdermal absorption
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal absorption of estradiol in normal subjects
Trial: 14673697
Drug: Transdermal absorption
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal absorption of estradiol in patients with polyneuropathy
Trial: 10871969
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin treatment at home
Trial: 10871969
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin treatment in hospital
Trial: 9663831
Drug: Lactulose 5
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lactulose 5 g
Trial: 9663831
Drug: Placebo 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 10 g
Trial: 8200722
Drug: Seaprose (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seaprose (90 mg/day for 10 days)
Trial: 24834887
Drug: 500 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/kg iodine load and 80 kV(p) tube voltage
Trial: 24834887
Drug: 400 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/kg iodine load and 80 kV(p) tube voltage
Trial: 24834887
Drug: 600 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/kg iodine load and 120 kV(p) tube voltage
Trial: 12395978
Drug: Diclofenac 75
RxNorm normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 75 mg alone
Trial: 16022753
Drug: Galactose (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galactose (50 g)/guar gum (2.5 g) load with standard breakfast (GG)
Trial: 16022753
Drug: Water (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (250 ml) with standard breakfast (W)
Trial: 1826823
Drug: Medroxy progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Medroxy progesterone acetate 500 mg i.m. twice weekly for 3 months
Trial: 29952137
Drug: Combined inspiratory
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined inspiratory and expiratory external resistance (2-20 cmH2 O/L/sec)
Trial: 27802950
Drug: Family Navigator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family Navigator (FN) intervention with daily contact addressing informational and emotional communication needs.
Trial: 5531862
Drug: Oral alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alcohol
Trial: 5531862
Drug: Oral alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alcohol in a patient with a completely denervated hand
Trial: 29259181
Drug: Fresh fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh fish (250 g twice weekly for 8 weeks)
Trial: 25780304
Drug: PEG‐Asc (2‐L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐Asc (2‐L polyethylene glycol with ascorbic acid 20 g)
Trial: 22632135
Drug: Psycho-educational program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psycho-educational program for caregivers (10 sessions of 90 minutes over 5 weeks) + antipsychotic drug treatment for patients
Trial: 19253021
Drug: Maitake liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maitake liquid extract at 0.1, 0.5, 1.5, 3, or 5 mg/kg twice daily for 3 weeks
Trial: 17312364
Drug: Skin protection
RxNorm normalized name: NeutrapHor 1% Skin Protection Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin protection ointment
Trial: 12234565
Drug: High-dose LMWH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose LMWH for thromboprophylaxis for the first postoperative week
Trial: 10212537
Drug: Short implants
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short implants in the posterior region of the maxilla
Trial: 10212537
Drug: Clinical parameters
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical parameters (bleeding, pocket depth, implant mobility)
Trial: 508702
Drug: Intramuscular Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular Fe dextran, 100 mg twice per week for 10-12 weeks
Trial: 508702
Drug: Oral Fe,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Fe, 120 mg/d, 6 d/week for 10-12 weeks
Trial: 508702
Drug: Intravenous Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Fe by total dose infusion of Fe dextran
Trial: 10065696
Drug: Inhaled salmeterol
RxNorm normalized name: salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol 400 microg
Trial: 10065696
Drug: Inhaled salmeterol
RxNorm normalized name: salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol 400 microg plus oral activated charcoal
Trial: 2394068
Drug: Femoral vein
RxNorm normalized name: Sus scrofa vein preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femoral vein infusion with single location dynamic scanning
Trial: 20448359
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of salvia miltiorrhiza and prednisolone
Trial: 12033092
Drug: Propofol 3
RxNorm normalized name: fospropofol 35 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 3 mg.kg‐1 and fentanyl 2 micrograms.kg‐1
Trial: 10087242
Drug: Prempak C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prempak C 0.625(R) hormone replacement therapy
Trial: 8649914
Drug: Nebulised budesonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised budesonide (2 mg)
Trial: 7018726
Drug: MER (methanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MER (methanol extraction residue BCG) immunotherapy during chemotherapy
Trial: 22806399
Drug: Apremilast 40
RxNorm normalized name: Apremilast
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Apremilast 40 mg once per day (treatment-extension phase)
Trial: 8782347
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine (720 ELISA units of antigen) administered according to the abbreviated schedule (two vaccinations given 2 weeks apart)
Trial: 8782347
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine (720 ELISA units of antigen) administered according to the standard schedule (two vaccinations given 4 weeks apart)
Trial: 8782347
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine (720 ELISA units of antigen)
Trial: 8782347
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine (720 ELISA units of antigen) with other 'travellers' vaccines
Trial: 1509550
Drug: Propofol (Diprivan)
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol (Diprivan) without prior administration of fentanyl
Trial: 6838691
Drug: Diet and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet and/or drugs
Trial: 24949549
Drug: SOD-melon concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOD-melon concentrate (10 mg per day for 12 weeks)
Trial: 28510491
Drug: Extra-fine BDP
RxNorm normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-fine BDP breath-actuated inhaler (Aerobec®/QVAR® Autohaler®) 100 μg b.i.d.
Trial: 23972645
Drug: Uncoated mini‐tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncoated mini‐tablets
Trial: 23972645
Drug: Coated mini‐tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coated mini‐tablet
Trial: 17823672
Drug: Buprenorphine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (1 mL injected into the joint space)
Trial: 17823672
Drug: Saline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (1 mL injected into the joint space)
Trial: 2177041
Drug: Itraconazole (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (4 mg per 1 kg of body weight, once daily for 6 weeks)
Trial: 6996516
Drug: Alcohol (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (three doses) during luteal phase
Trial: 26262586
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training plus low dose of dopamine agonists (DA)
Trial: 15606570
Drug: Subcutaneous octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous octreotide 100 microg
Trial: 11438328
Drug: 0.060 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.060 mg Org 30659
Trial: 11438328
Drug: 0.120 mg
RxNorm normalized name: ETONOGESTREL 0.120 mg in 1 d / ETHINYL ESTRADIOL 0.015 mg in 1 d VAGINAL RING [EluRyng]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.120 mg Org 30659
Trial: 28472240
Drug: Goserelin (gonadotropin-releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin (gonadotropin-releasing hormone agonist) administered before and during chemotherapy
Trial: 26035199
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg venlafaxine + 60‐minute light of 7000 lux daily at 7:00 AM (venlafaxine + bright light therapy)
Trial: 26035199
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg venlafaxine daily at 7:00 AM
Trial: 21251178
Drug: LY2189265 (LY)
RxNorm normalized name: LYS
DrugBank: Lysine (DB00123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LY2189265 (LY) 1 mg or higher doses
Trial: 21251178
Drug: LY2189265 (LY)
RxNorm normalized name: LYS
DrugBank: Lysine (DB00123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LY2189265 (LY) 0.3 mg
Trial: 21251178
Drug: LY2189265 (LY)
RxNorm normalized name: LYS
DrugBank: Lysine (DB00123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LY2189265 (LY) 0.05, 0.3, 1, 3, 5, or 8 mg
Trial: 19254299
Drug: Deliberate prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deliberate prescription of impression materials
Trial: 9314089
Drug: Tiazac (diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiazac (diltiazem HCl capsule formulation)
Trial: 9314089
Drug: Cardizem CD
RxNorm normalized name: Cardizem CD
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cardizem CD (extended-release diltiazem)
Trial: 9314089
Drug: Dilacor XR
RxNorm normalized name: Dilacor XR
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dilacor XR (extended-release diltiazem)
Trial: 2195863
Drug: Dipyridamole 150
RxNorm normalized name: dipyridamole 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole 150 mg/day
Trial: 24224449
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (vitamin C) supplementation at a dose of 600 mg per 24 hours during chemotherapy
Trial: 16979993
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) [1.5-2.0 g/d]
Trial: 10938494
Drug: Metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol succinate CR/XL added to standard therapy
Trial: 9052464
Drug: Intravesical pentosanpolysulphate
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical pentosanpolysulphate (PPS) 300 mg in 50 mL of 0.9% sodium chloride, applied twice a week for 3 months
Trial: 8398961
Drug: Intraarticular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular morphine (5 mg in 25 ml dilution)
Trial: 8398961
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (25 ml saline)
Trial: 3742049
Drug: Danazol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (600 mg/d for 8 weeks)
Trial: 28480658
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with Alendronate (ALEN) and Hormonal Therapy (HT)
Trial: 19383314
Drug: Epidermal growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidermal growth factor receptor inhibitors
Trial: 16621768
Drug: Oral glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral glutamine supplementation (4 g/m2/day) during chemotherapy
Trial: 2227076
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg ursodeoxycholic acid (UDCA) twice daily for 14 days
Trial: 30190512
Drug: Gene therapy
RxNorm normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene therapy (ADV-TK, 5 × 10^12/ml) administered one or two times before operation
Trial: 26620101
Drug: BIT225 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIT225 (400 mg twice daily)
Trial: 10172545
Drug: Control district
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control district with only government drug supply
Trial: 31109368
Drug: TMQLB group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMQLB group 1 (0.4 ml/kg body weight 0.5% ropivacaine)